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ABSTRACT
Chronic myeloid leukemia (CML) is a clonal myeloprolif-
erative disorder characterized by a chromosome
translocation that generates the Bcr-Abl oncogene en-
coding a constitutive kinase activity. Despite remarkable
success in controlling CML at chronic phase by Bcr-Abl
tyrosine kinase inhibitors (TKIs), a signiﬁcant proportion
of CML patients treated with TKIs develop drug resis-
tance due to the inability of TKIs to kill leukemia stem
cells (LSCs) that are responsible for initiation, drug re-
sistance, and relapse of CML. Therefore, there is an ur-
gent need for more potent and safer therapies against
leukemia stem cells for curing CML. A number of LSC-
associated targets and corresponding signaling path-
ways, including CaMKII-γ, a critical molecular switch for
co-activating multiple LSC-associated signaling path-
ways, have been identiﬁed over the past decades and
various small inhibitors targeting LSC are also under
development. Increasing evidence shows that leukemia
stem cells are the root of CML and targeting LSC may
offer a curable treatment option for CML patients. This
review summarizes the molecular biology of LSC and its-
associated targets, and the potential clinical application
in chronic myeloid leukemia.
KEYWORDS chronic myeloid leukemia (CML), leukemia
stem cells (LSCs), tyrosine kinase inhibitors (TKIs),
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INTRODUCTION
It is well established that cancers depend on a small
population of “cancer stem cells” (CSCs) for maintaining their
uncontrolled growth. Early insight into the molecular
pathogenesis of cancer stemmed from the discovery of ac-
tivating oncogenes, such as Bcr-Abl oncogene and its con-
stitutively active protein tyrosine kinase, in CML (NOWELL
and HUNGERFORD, 1960; Rowley, 1973; Druker, 2008).
The Bcr-Abl oncogenic tyrosine kinase is responsible for
initiating and maintaining the leukemia phenotype of CML
cells. This oncoprotein is also responsible for the phospho-
rylation, activation and dysregulation of intracellular signaling
proteins that regulate the survival and growth of progenitor
cells in the bone marrow (Tauchi et al., 1994; Kabarowski
and Witte, 2000). Although tyrosine kinase inhibitors (TKIs)
for Bcr-Abl oncoprotein revolutionized the treatment of CML
at chronic phase (CML-CP), 25% of TKI-naive patients and
50%–90% of patients with TKI-resistance contain leukemic
clones expressing TKI-resistant Bcr-Abl kinase mutants
(Slupianek et al., 2013). Studies have shown that a number
of factors, including activation of critical signal transduction
pathways, cell cycle alterations, abnormal epigenetic events
and aberrant microenvironment from the hematopoietic
niche, contribute to the enhanced survival and continued
growth of CML stem/progenitor cells. This review will focus
on the molecular biology of LSC and its-associated targets,
and the potential clinical application in chronic myeloid
leukemia.
LEUKEMIA STEM CELLS OF CHRONIC MYELOID
LEUKEMIA
Stem cells are deﬁned as functional rather than morpho-
logical or any other physical feature. The current deﬁnition of
stem cell remains the same as it established by McCulloch
and Till, which are characterized by three distinct properties:
self-renewal, differentiation capability, and proliferative ca-
pacity (Molofsky et al., 2005). These properties make stem
cells to produce and maintain a diverse and specialized
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group of cells. In addition to maintaining their undifferentiated
state by self-renewal, stem cells also generate progenitors
that differentiate to form cells of multiple lineages upon
successive divisions.
CML has long been considered as a stem cell disease,
but detailed characteristics of its stem cells have not been
fully elucidated to date. Because CML has the propensity to
evolve from a chronic phase to accelerated phase and ﬁnally
to blast crisis phase, one can pinpoint the phase and de-
velopmental stage at which mutations arise. Hence, CML is
an important paradigm for understanding both genetic and
epigenetic events that drive aberrant stem and progenitor
cell differentiation, self-renewal and survival during both
early and advanced phases of disease (Lowe and Sherr,
2003). In vitro studies using long-term culture-initiating cell
(LTC-IC) assays showed the presence of pluripotent stem
cells of malignant origin in patients with CML (Chen et al.,
1994). The majority of CML progenitors were found to have a
higher proliferative capacity compared to normal progenitors,
suggesting that most CML progenitors were actively cycling
(Eaves et al., 1998).
The concept that cancer/leukemia stem cells (CSCs/
LSCs) are responsible for initiation, drug resistance, and
relapse of cancers has inﬂamed this area of research and
the importance of CSCs has been demonstrated in a variety
of tumors (Morrison et al., 1995; Weissman, 2000; Al-Hajj
et al., 2003). In CML and other malignancies, studies have
shown that LSCs are able to self-renew, which leads to
therapeutic resistance and disease progression (Olsson
et al., 2014).
A model for leukemogenesis shows that the malignant
transformation of normal hematopoietic stem/precursor cells
would give rise to LSCs (Dash et al., 2002; Zhao et al., 2004;
Strathdee et al., 2007), which retains the key characteristics
of self-renewal and proliferative capacity but do not differ-
entiate to mature cells. Because current therapies for leu-
kemia are designed based on the general biological
properties of malignant blast cells with proliferation potential,
whereas LSCs are frequently in a quiescent state. Thus,
current strategies do not effectively eliminate the LSCs as
well as the disease (Holyoake et al., 1999).
Quiescence of leukemia stem cells
Although the precise molecular mechanism of LSC-mediat-
ed resistance to current therapies has not been fully eluci-
dated, one critical factor might be the quiescence of LSC that
allows this population cells to evade the targeting by current
therapies. In CML, abnormal tyrosine kinase-directed phos-
phorylation and mislocalization of cell cycle proteins have
been implicated in deregulation of the cell cycle in Bcr-Abl
expressing cells, which means that CML quiescent LSCs are
TKI resistant and represent a Bcr-Abl kinase-independent
disease reservoir (Cramer et al., 2008). Leukemia stem cells,
particularly those in a quiescent state, are highly resistant to
current chemotherapies and targeted therapies, resulting in
disease relapse (Ito et al., 2008; Kaminska et al., 2008). In
addition, signaling molecules involved in cell survival and
self-renewal, which are the two critical characteristics of
quiescent LSC, have been linked to key regulators of the cell
cycle.
Studies have revealed that LSCs residing in the bone
marrow niche are dormant and resistant to traditional che-
motherapies. Speciﬁc signals from the surrounding stromal
cells might promote LSCs cell cycle arrest and allow them to
persist even during treatment with TKI therapies. Imatinib
mesylate (IM), the ﬁrst drug designed to target the Bcr-Abl
kinase, induces hematologic and cytogenetic remissions in
the majority of CML patients at chronic phase, however, the
Bcr-Abl kinase domain mutations portend a greater risk of
loss of complete cytogenetic remission (CCR) (Molofsky
et al., 2005). Ultimately, regardless of greatly reduced mor-
tality rates with Bcr-Abl targeted therapy, a signiﬁcant pro-
portion of patients are expected to develop TKI resistance
driven by quiescent LSCs, which may be a reservoir for
disease progression to blast crisis. Several studies demon-
strate that a quiescent population of CML stem cells
(CD34+CD38–CD45RA–CD71–HLA–DRlow) with Bcr-Abl ki-
nase domain mutations, detectable prior to initiation of ima-
tinib therapy, gives rise to leukemia cells that persist
because they are inherently resistant to imatinib (Sorel et al.,
2004; Molofsky et al., 2005; Barnes and Melo, 2006; Jiang
et al., 2007; Jorgensen et al., 2007; Niemann et al., 2007;
Wodarz, 2008; Olsson et al., 2014). This may be attributable
in part to quiescent LSCs residing in the protective niches
that acquire additional mutations over time. In addition, qui-
escent CD34+ progenitors at chronic phase increases the
expression levels of chemokines associated with stem cell
mobilization (Dierks et al., 2008). Also, several oncogenic
transcription factors that regulate cell-fate decision in HSCs
and have been implicated in myeloid leukemia, such as
MEIS1 and HOXA9, were found to be overexpressed in
blast-crisis CML (Jamieson et al., 2004a, b). HOXA9 over-
expression leads to the transformation of primary bone
marrow cells through speciﬁc collaboration with MEIS1
(Kroon E et al., 1998). It has been suggested that HOXA9
forms ternary complexes with PBX2 and MEIS1 in myeloid
leukemic cells (Shen WF et al., 1999). These results indicate
that the ternary complex, including HOXA9, plays an im-
portant role in inducing leukemia, Cooperative activation of
MEIS1 and HOXA9 perturbs myeloid differentiation and
eventually leads myeloid progenitors to leukemia.
Self-renewal and survival of leukemia stem cells
Deregulation of programmed cell death or apoptosis allows
cancer stem cells to propagate even as they detach from the
niche and accumulate genetic mutations. In CML, resistance
to apoptosis begins with Bcr-Abl, and notably, the ﬁnal
consequence of Bcr-Abl inhibition with imatinib is induction
of apoptosis (Holyoake et al., 1999). CML stem cell resis-
tance to apoptosis involves the aberrant expression of the
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Bcl-2 family of apoptosis-regulatory proteins, including anti-
apoptotic members, such as Bcl-2 and Mcl-1, and pro-
apoptotic members, such as Bad and Bim (Bedi et al., 1994;
Cramer et al., 2008). In addition, activation of the Wnt/β-
catenin pathway leads to increased c-myc expression and
ultimately results in upregulation of Bcl-2 family proteins.
However, Neviani et al. reported that protein phosphatase
2A (PP2A)-activating drugs (PADs) can markedly reduce the
survival and self-renewal of CML quiescent HSCs, but not
normal quiescent HSCs through Bcr-Abl kinase-independent
and PP2A-mediated inhibition of JAK2 and β-catenin (Ne-
viani et al., 2013). In addition, autocrine TNF-alpha produc-
tion supports the survival of CML stem and progenitor cell
and enhances their proliferation (Gallipoli et al., 2013).
Several important apoptosis proteins are also highly
regulated by the PI3K/Akt pathway (Cramer et al., 2008). Akt
directly inhibits Bad and Bax and modulates the activity of
transcription factors such as those from the NF-κB and FoxO
families (Ito et al., 2008; Kaminska et al., 2008). NF-κB
protein activation leads to its nuclear localization, where it
then activates the transcription of a number of pro-survival
molecules including Bcl-2, Bcl-xl, and various caspase in-
hibitors (Cramer et al., 2008). The importance of these
transcription factors in CML has been highlighted by the fact
that NF-κB is activated in transgenic models of CML and that
Bcr-Abl can activate NF-κB (Kaminska et al., 2008). FoxO
transcription factors, on the other hand, are targeted for
proteolysis via Akt-mediated signaling (Khorashad et al.,
2008). These factors normally induce the transcription of pro-
death molecules including Bim and FasL. In CML, Bcr-Abl
causes constitutive repression of FoxO3a by continued ac-
tivation of Akt, leading to another mechanism of Bcr-Abl-
mediated apoptotic resistance (Khorashad et al., 2008;
Scheller et al., 2013). Finally, Akt can inhibit GSK3β activity.
Thus, the Akt pathway is involved in apoptosis regulation via
regulation of GSK3β in CML. Although many survival path-
ways are upregulated in CML, they are also active in normal
stem cells. Thus, revealing the differential expression pro-
ﬁles of survival-related genes between normal hematopoietic
stem cells and leukemia stem cells will be critical for de-
signing therapies that selectively eradicate CML stem cells
while sparing normal stem cells.
Aberrant differentiation of leukemia stem cells
In CML progenitors at blast crisis, the characteristic block of
myeloid differentiation is resulted from Bcr-Abl and MAPK
(ERK1/2)-induced hnRNP-E2 RNA-binding protein-mediated
suppression of C/EBPα expression (Chang et al., 2007). The
imatinib and nilotinib resistance, which is derived in part from
autocrine granulocyte-macrophage colony-stimulating factor
(GM-CSF) secretion in response to adaptive JAK2/STAT5
signaling in granulocyte-macrophage progenitors (GMPs),
may be overcome by JAK2 inhibitor (Wang et al., 2007;
Gallipoli et al., 2014). In addition to cell autocrine effects,
study results from a tetracycline-off mouse model revealed
that osteopontin, an essential component of the stem cell
niche, was upregulated in Bcr-Abl positive cells (Jamieson
et al., 2004a, b). Similarly, osteopontin levels were higher in
the serum of patients with CML and contributed to maintain
the malignant clones at extramedullary sites (Jamieson
et al., 2004a, b). A genetically deﬁned mouse model of blast
crisis CML demonstrated that coincident overexpression of
genes that skew differentiation, such as Bcr-Abl and NUP98/
HoxA, also resulted in the production of an imatinib-resistant
LSC population (Dash et al., 2002; Neering et al., 2007).
Together these data suggest that the block of differentiation
and the enhancement of self-renewal in CML stem cells may
be a critical step of disease progression.
SIGNALING PATHWAYS OF LEUKEMIA STEM
CELLS
Self-renewal is an essential property of stem cells, but the
aberrant activation of self-renewal related signaling path-
ways has been recognized as a hallmark of cancer (Lowe
and Sherr, 2003; Jamieson et al., 2004a, b). Wnt genes
encode small secreted proteins existing in all animal gen-
omes, and Wnt signaling is involved in virtually every aspect
of embryonic development and also controls homeostatic
self-renewal in a number of adult tissues. Studies have
shown that the developmental pathways, such as the Wnt
signaling pathway and the polycomb-group protein Bmi1, are
involved in the regulation and expansion of LSCs during
CML blast crisis (Chen et al., 1994; Reya et al., 2001; Saudy
et al., 2014). The Wnt pathway, which is critical for HSC self-
renewal and interaction with bone marrow niche, was found
to be activated during progression to advanced phase in
CML patients at blast crisis (Lowe and Sherr, 2003). Self-
renewal capacity is normally absent in GMP, but some
studies reveal that inappropriate activation of the Wnt path-
way in GMPs endows these cells with self-renewal capacity,
as measured by generation of replatable myeloid colonies
(Lowe and Sherr,2003), suggesting that these GMPs ac-
quires a key property of a leukemia stem cell. β-Catenin is
also essential for survival of LCSs. In some cases β-catenin
activation is associated with deregulation of GSK3β, an
essential negative regulator of β-catenin, in both stem and
progenitor cells, while other patients exhibit defective ex-
pression of another negative regulator of the pathway-axin 2
(Liu et al., 2005; Quaiser et al., 2006). The progression to
myeloid blast crisis can be averted in a β-catenin knockout
mouse model of CML (Sengupta and Banerjee, 2007).
Aberrant activation of another self-renewal program,
Sonic hedgehog, was shown to induce expansion of LSCs in
a mouse model of CML, while another study reported that
there might be a cross-talk between sonic hedgehog, Wnt,
and notch pathways in CML (Williams et al., 2008; Hu et al.,
2009). The Hedgehog (Hh) signaling pathway is a develop-
mental pathway that has been shown to play a role in pri-
mitive and adult hematopoiesis (Morrison et al., 1995). The
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Hh pathway activity is required for maintaining the normal
and leukemia stem cells, and raising the possibility that the
drug resistance and disease recurrence might be avoided by
targeting the essential stem cell maintenance pathway.
Strathdee et al. reported that the Hh signaling was activated
in LSCs and differentiated hematopoietic cells through the
upregulation of Smo, an essential component of the Hh
pathway (Strathdee et al., 2007). Constitutively activation of
Smo increased CML stem cell number and accelerated
disease (Zhao et al., 2009), while the loss of Smo impaired
HSC renewal (Strathdee et al., 2007).
CaMKII comprises a family of closely related kinases with
four isoforms (α, β, γ, and δ). Among these four isoforms,
CaMKII-γ has been shown to be the major one overex-
pressed in myeloid cells and its potential role as a regulation
of leukemia (Si et al., 2007), inhibition of CaMKII activity
correlated with enhanced apoptosis (Hojabrpour et al.,
2012). Also, CaMKII-γ regulates many fundamental cellular
functions and has been implicated in the pathogenesis of
several diseases (Si et al., 2007; Si and Collins, 2008). Our
study found that both total and phosphor CaMKII-γ proteins
were highly expressed in the CD34+/CD38− CML LSCs, but
low in CD34− CML cells, CD34+ HSCs from healthy cord
bloods and normal blood cells, suggesting that CaMKII-γ
might play a critical role in the survival and proliferation of
CML LSCs. CaMKII-γ is a speciﬁc and critical target of
berbamine for its anti-leukemia activity and berbamine se-
lectively binds to CaMKII-γ by targeting ATP binding pocket
(Gu et al., 2012). Most importantly, CaMKII-γ is a critical
molecular switch of multiple cancer-related signaling path-
ways (Fig. 1), such as NF-κB (Hughes et al., 2001; Gu et al.,
2012), Wnt/β-catenin (Si and Collins, 2008; Gu et al., 2012),
ERK1/2, FoxO1, AKT, and Stat3 signaling pathways
(Hughes et al., 2001; Marganski et al., 2005; Ang et al.,
2007; Si et al., 2007; Liu et al., 2008; Bouallegue et al., 2009;
Timmins et al., 2009; Gu et al., 2012).
Recently, Gerber et al. identiﬁed 97 genes that were dif-
ferentially expressed in CML versus normal stem and pro-
genitor cells by performing genome-wide transcriptome
analysis of highly reﬁned CML and normal stem and pro-
genitor cell populations using exon microarrays. Further
analyses of the LSCs revealed dysregulation of normal cel-
lular processes; downregulation of pro-differentiation and
TGF-beta/BMP signaling pathways; upregulation of oxidative
metabolism and DNA repair pathways; and activation of in-
ﬂammatory cytokines (Gerber et al., 2013). These data
greatly contribute to understanding the molecular changes of
LSCs and developing novel therapies for eradicating LSCs
and even achieving curable effect of CML.
LEUKEMIA STEM CELL-RELATED TRANSCRIPTION
FACTORS
Progression of CML is associated with transcription factor-
induced aberrant lineage priming of stem and progenitor
cells. The role of transcription factor deregulation in the dif-
ferentiation of CML stem cells was demonstrated in a
transgenic mouse model with deﬁciency of a transcription
factor, Jun B. Jun B deﬁciency led to the development of a
CML-like disease with a propensity for myeloid differentiation
in which serial transplantation potential existed only at the
level of HSC (Passegue et al., 2001; Chu et al., 2005).
Moreover, GM-CSF-mediated survival and proliferation of
Jun B-deﬁcient GMP was associated with anti-apoptotic
proteins Bcl-2 and Bcl-x, and cell cycle regulators p16ink4a
and c-Jun (Chu et al., 2005). The transcriptional repressor
Bmi1, which is normally restricted to the stem-cell compart-
ment, was found to be overexpressed in the aggressive
forms of CML that progress to blast crisis within 3 years and
during advanced phases of this disease (Chang et al., 2007).
The E-twenty six (ets) transcription factor GA binding
protein (GABP) is a tetrameric transcription factor complex
that contains GABPα and GABPβ proteins. Deletion of
GABPα induced cell cycle arrest and profound loss of he-
matopoietic progenitor cells in bone marrow (Yang et al.,
2013). Recently, Yang et al. identiﬁed the serine-threonine
kinase protein kinase D2 (PRKD2) as a potential effector of
GABP in HSCs through bioinformatic screen. PRKD2 can
rescue the growth of GABPα-null Bcr-Abl-expressing cells
whereas inhibiting PRKD2 expression decreased cell cycling
(Yang et al., 2013). These data indicate that GABP is
essential for the cell cycle entry of HSC and CML develop-
ment and may offer a potential therapeutic target for CML.
GATA-2, an important myeloid transcription factor, has
been proven to be upregulated in CML CD34+ cells, whereas
stem cell fate determination by the large family of Hox genes
is negatively regulated by Bmi1 (Cao et al., 2005; Mohty
et al., 2007). Transcription factors HoxA9 and HoxB4 are
better known for their transforming potential via enhancing
HSC self-renewal and abnormal myelopoiesis upon
upregulation (Cao et al., 2005; Strathdee et al., 2007).
Downregulation of Hox genes, such as HoxA5, impairs
myelopoiesis, suggesting differentiation block at the level of
hematopoietic stem cells. Interestingly, hypermethylation-
mediated inactivation of HoxA4 and HoxA5 was found in
34% of CD34+ cells from patients with chronic phase CML
whereas it was observed in up to 90% of patients with CD34+
CML in blast crisis (Strathdee et al., 2007). Moreover, this
hypermethylation-mediated inactivation of HoxA4 and
HoxA5 was associated with a poor prognosis in other mye-
loid and lymphoid malignancies and might be a biomarker of
more severe disease (Strathdee et al., 2007).
EPIGENETIC EVENTS IN LEUKEMIA STEM CELLS
Epigenetic alterations include DNA methylation, histone
modiﬁcations, and miRNA in the permanent changes of gene
expression, which controls the leukemia phenotype. Among
these, DNA methylation and histone modiﬁcation play an
important role in leukemogenesis (Esteller, 2008; Jones
et al., 2002). For instance, aberrant DNA methylation could
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silence the expression of tumor suppressor genes in leuke-
mia whereas overexpression of the histone methyltrans-
ferase, EZH2, a subunit of the polycomb group repressive
complex 2 (PRC2) promotes oncogenesis (Momparler et al.,
2012).
SIRT1 deacetylase is a multifunctional protein and can
potentially regulate the acetylation of several transcription
factors, including p53 (Luo et al., 2001), Ku70, and FoxOs
(Brooks and Gu, 2009). Recent studies demonstrate that
SIRT1 deacetylase not only promotes acquisition of genetic
mutations for drug resistance in CML cells but also play a
critical role in maintaining the survival of CML LSCs (Wang
et al., 2013; Li et al., 2012). SIRT1 activation promotes re-
sistance of CML stem cells to tyrosine kinase inhibitors and
acquisition of BCR-ABL mutations for acquired resistance.
Consistently, SIRT1 was expressed at higher levels in hu-
man CML CD34+ cells than in normal CD34+ cells. More-
over, inhibition of SIRT1 increased apoptosis in LSC of
chronic phase and blast crisis CML and reduced their growth
in vitro and in vivo. The inhibitory effects of SIRT1 targeting
on CML cells depend on p53 expression and acetylation.
Importantly, SIRT1 inhibition had less of an effect on prolif-
eration and apoptosis of normal CD34+ cells, suggesting that
SIRT1 might be a new target for eliminating CML cancer
stem cells. In addition, SIRT1 inhibition in combination with
BCR-ABL tyrosine kinase inhibitors might be a novel ap-
proach to eliminate leukemic stem cells and residual disease
in CML.
Alternative pre-mRNAsplicing (AS) is an epigenetic process
that greatly diversiﬁes the repertoire of the transcriptome
(Adamia et al., 2013). “Splicing programs” typically react to in-
dividual changes with considerable effects in cell proliferation,
cell survival, and apoptosis, although the changes in these in-
dividual splicing events are small. Evaluation of AS events in
CMLcanbeused to identifynewdiseasemarkersand sensitive
targets in order to overcome the current limits of small molecule
inhibitors for the treatment of patients with CML.
CHEMOKINES AND MICROENVIRONMENT OF
LEUKEMIA STEM CELLS
Chemokine is a large protein family that can be divided into
subfamilies on the basis of structural motifs. An important
property of chemokines is its leukocyte chemotaxis.
Chemokines regulate their biological effects via interactions
with a family of 7-transmembrane G protein-coupled recep-
tors. Chemokines, such as stromal-derived factor-1 (SDF-1/
CXCL12) secreted by stromal cells, attracts cancer cells by
acting its cognate receptor CXCR4 (Peng et al., 2012).
Previous studies indicated that chemokines, which were
expressed on hematopoietic and nonhematopoietic tumor
cells, were reported to mediate chemotaxis of CD34+ stem
cells, and to play a critical role in the homing and retention of
these cells in the microenvironment of bone marrow (Bleul
et al., 1996; Kortesidis et al., 2005). In addition, SDF-1 was
found to function as both a chemoattractant and as a
modulator of cellular growth/survival (Naiyer et al., 1999;
Cashman et al., 2002; Liu et al., 2011)
It is unclear why under certain conditions this may pro-
mote uncontrolled proliferation, while in other cases cell
quiescence may be favored. However, it is possible that the
cues from the microenvironment might be involved. The
studies support important, new concepts regarding the
contribution of leukemia-induced alterations in the BM mi-
croenvironment to a selective growth advantage to leukemic
compared with normal long-term hematopoietic stem cell
(LTHSC) and have relevance to our understanding of the
response and resistance to TKI at the organismal level
(Zhang et al., 2012). Also, evidence provides new insight into
the potential contribution of the microenvironment to the
initiation and progression of myeloid disorders and leukemia,
and may provide a unique area for the development of
combination therapeutic strategies aimed at eradicating the
resistant LSC population in CML (Hobbs et al., 1998; Liotta
and Kohn, 2001). Signals from the microenvironment have a
profound inﬂuence on the maintenance and/or progression
of hematopoietic cancers.
TARGETING OF LEUKEMIA STEM CELLS
Despite the curable effect for CML by allogeneic he-
matopoietic cell transplantation, high transplant-related
morbidity and mortality has greatly reduced its use since the
development of molecularly targeted therapy (Karanes et al.,
2008). Currently, there are three kinds of therapeutic drugs
for CML: traditional chemotherapy agents, TKIs, and LSC
Molecular switch
CaMKII-γ







Figure 1. CaMKII-γ promotes self-renewal of leukemia stem
cells via co-activating multiple signaling pathways.
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inhibitors, and their working models are shown in Fig. 2.
Before the development of Bcr-Abl-targeted therapy, treat-
ment of CML patients at chronic phase is focused primarily
on achieving hematologic control, and cytogenetic remission
is rare. Moreover, most patients will progress to blast crisis
within a few years. Currently, TKIs, which are potent in-
hibitors of Bcr-Abl protein kinases, c-Kit and the platelet-
derived growth factor receptor (Valk-Lingbeek et al., 2004;
Slupianek et al., 2013), are widely used for treatment of CML
due to their highly efﬁcient control of CML at chronic phase.
However, These TKIs are unable to kill CML stem cells
(Graham et al., 2002). A large number of studies have
demonstrated that these TKIs can readily kill most CML cells
but only display cytostatic effect on the primitive CML LSCs
(Holtz et al., 2002). Consistent with these data, CD34+ stem
cells from CML patients with complete cytogenetic re-
sponses were found to be of malignant origin with the ca-
pacity to give rise to CML-BC (Bhatia et al., 2003). These
ﬁndings indicate that a reservoir of CML LSCs is still main-
tained in patients who do not show evidence of disease.
The leukemia stemcells inpatientswithCMLarewell known
to be resistant to conventional chemotherapy and may also be
relatively resistant to Bcr-Abl-targeted drugs. Studies have
demonstrated the persistence of quiescent CML stem cells that
are impervious to Bcr-Abl inhibitor therapy and contribute to
disease progression (Holyoake et al., 1999; Chu et al., 2005;
Barnes andMelo, 2006; Copland et al., 2006; Jorgensen et al.,
2007). The precise sequence of molecular events leading to
recalcitrance to Bcr-Abl inhibitor therapy as well as the cellular
framework in which they occur has not been elucidated com-
pletely. As the properties of leukemia stem cells become better
deﬁned, it is possible to evaluate current therapeutic strategies
correctly. Identiﬁcation of therapeutic targets, which are in-
volved in the survival of CML LSCs such as bcl-2; the self-
renewal suchas sonicHh, bmi-1, notch, andWnt; and the block
differentiation such as JAK2/STAT5 activation and HOX gene
hypermethylation, will contribute to target LSCs effectively
using combinations of small molecule inhibitors and demethy-
lating agents. (Guzman et al., 2005; Neviani et al., 2005; Guz-
manet al., 2007;Mohty et al., 2008;Bhattacharyyaet al., 2009).
Several bcl-2 family member inhibitors are currently under
development, JAK2/STAT5 inhibitors are currently being
tested in clinical trials and self-renewal pathway inhibitors
such as gamma-secretase inhibitors have been used
clinically. Several Wnt and sonic hedge-hog inhibitors, which
are being evaluated in preclinical models, show promise
clinically for eradicating committed progenitors that have
aberrantly gained self-renewal capacity. In addition, imple-
mentation of strategies to augment both innate and adaptive
immune responses against CML progenitors may accelerate
disease eradication (Rezvani et al., 2007; Yong et al., 2008).
The eukaryotic translation initiation factor 4E (eIF4E) is a
potent oncogene elevated in an estimated 30% of human
cancers (Culjkovic et al., 2009; Siddiqui et al., 2012), and the
eIF4E protein provides the critical interface between mRNA,
recruitment of eIF4A and eIF4G, and the 40S ribosomal
subunits. The activity of eIF4F is generally regulated by al-
tering the phosphorylation state of the eIF4E component.
Increased phosphorylation of eIF4E correlates with en-
hanced translation in cells stimulated with mitogens, growth
factors, or serum (Kaspar et al., 1990; Marino et al., 1989).
Recently, studies showed that over-phosphoeylation of
eukaryotic translation initiation factor 4E (eIF4E) led to in-
creased β-catenin protein synthesis, whereas MAP kinase
interacting serine/threonine kinase (MNK) kinase-dependent
eIF4E phosphorylation at serine 209 is required for nuclear
translocation and activation of β-catenin. These ﬁndings
suggest that inhibiting phosphorylation of eIF4E may be
therapeutically useful in CML-BC (Lim et al., 2013).
RAD51 (Rec A homolog of E. coli) is a polymorphic gene
and one of the central proteins in homologous recombination-
DNA-double-stand breaks (HR-DNA-DSB) repair pathway,
which is vital in maintaining genetic stability within a cell












Figure 2. Model of different therapies for chronicmyeloid leukemia.Hemotherapy kills both leukemia cells and normal hematopoietic
stem cells. TKIs selectively kill leukemia cells but not leukemia stem cells. LSC inhibitors selectively kill leukemia stem cells.
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critical role for cancer cell proliferation and survival, and often
contributes to drug-resistance, therefore been proposed as an
alternative and supplementary strategy for cancer treatment.
IBR2, a novel small molecule that inhibits cancer cell growth
and induces apoptosis by inducing proteasome-mediated
RAD51 protein degradation, signiﬁcantly prolonged animal
survival in a murine imatinib-resistant CMLmodel bearing the
T315IBcr-Ablmutation.Moreover, IBR2effectively inhibits the
proliferation of CD34+ progenitor cells from CML patients,
suggesting that small molecule inhibitors of RAD51 may pro-
vide a novel class of broad-spectrum therapeutics for difﬁcult-
to-treat cancers (Zhu et al., 2013).
Abetter understandingof themolecular biologyof leukemia
stem cells will lead to designing more effective therapies for
CML. The challenge includes identiﬁcation of differences be-
tween leukemia stem cells and their normal stem cell coun-
terparts, anddemonstrationof complete control of leukemiaby
targeting these cancer stem cells. Recent advances in these
areas have identiﬁed several novel target candidates that
represent important avenues for future therapeutic ap-
proaches aimed at selectively eradicating the LSC population
while sparing normal hematopoietic progenitors in patients
suffering from chronic myeloid leukemia.
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